Legato Capital Management LLC Has $1.41 Million Holdings in Glaukos Co. (NYSE:GKOS)

Legato Capital Management LLC grew its position in shares of Glaukos Co. (NYSE:GKOS) by 85.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,381 shares of the medical instruments supplier’s stock after purchasing an additional 4,309 shares during the quarter. Legato Capital Management LLC’s holdings in Glaukos were worth $1,407,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Louisiana State Employees Retirement System raised its stake in Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $4,003,000 after buying an additional 100 shares during the last quarter. HighTower Advisors LLC grew its holdings in Glaukos by 3.3% during the 3rd quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock worth $416,000 after acquiring an additional 103 shares during the period. Values First Advisors Inc. bought a new position in shares of Glaukos in the 3rd quarter worth about $25,000. New York State Teachers Retirement System lifted its stake in shares of Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after purchasing an additional 200 shares during the period. Finally, KBC Group NV boosted its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Price Performance

GKOS stock opened at $143.80 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The business has a 50-day simple moving average of $151.20 and a two-hundred day simple moving average of $137.79. The company has a market capitalization of $7.93 billion, a P/E ratio of -47.62 and a beta of 1.04. Glaukos Co. has a 52-week low of $83.90 and a 52-week high of $163.71.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GKOS. BTIG Research lifted their target price on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Truist Financial lifted their price objective on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Stephens raised shares of Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Monday, December 2nd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and an average price target of $151.08.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,328 shares of company stock worth $2,289,521 over the last 90 days. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.